Company: DARE
Filing Date: 2025-11-13
Form Type: 10-Q
Source: 0001401914-25-000050
Chunk: 113

Company: Dare Bioscience, Inc.
Filing Date: 2025-11-13
Form: 10-Q
Item: Part I, Item 2
Chunk 113
---
i.e., without deducting the amount of contra R&D expense for the applicable program(s). See footnote (3) below.2. For the nine months ended September 30, 2025, amount also includes expenses for DARE to PLAY Sildenafil Cream.3.These contra R&D expenses were recognized as follows for the nine months ended September 30, 2025 and 2024: (a) Ovaprene, $1.9 million, and $0, respectively; (b) other advanced clinical stage programs, $2.2 million and $0 respectively, (c) Phase 1 and Phase 1-ready clinical stage programs, $0.3 million and $0.7 million, respectively; and (d) preclinical stage programs, $6.4 million and $5.1 million, respectively.

The decrease of approximately $6.1 million in R&D expenses for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024 was primarily attributable to (i) an increase in contra R&D expenses, (ii) a decrease in manufacturing costs related to Ovaprene, (iii) a decrease in costs related to development activities for Sildenafil Cream, (iv) a decrease in costs related to development activities for DARE-HRT1, and (v) a decrease in personnel costs, partially offset by increases in costs related to development activities for (A) our other advanced clinical stage programs —primarily attributable to our DARE-HPV program, (B) our pre-clinical and other development programs - primarily attributable to DARE-LARC1, and (C) our Phase 1 and Phase 1-ready clinical stage programs —primarily attributable to our DARE-PTB1 program. Contra R&D expenses for the nine months ended September 30, 2025 and 2024 primarily offset direct program costs for DARE-LARC1. 

40

Royalty expenses

Royalty expenses for the nine months ended September 30, 2024 related to our license agreement with MilanaPharm and our royalty interest financing agreement with UiE.

Other income (expense)

Sale of royalty and milestone rights, net

The decrease of $20.4 million in other income for the nine months ended September 30, 2025 as compared to the nine months ended September 30, 2024 was due to the proceeds we received in April 2024 under the